Lundbeck Cuts 150 R&D Jobs To Control Costs Ahead Of Key Patent Expiry
This article was originally published in The Pink Sheet Daily
Danish pharma increases investment in new product launches as it prepares for loss of patent protection on its lead product, escitalopram.
You may also be interested in...
Candidates for the post in the Danish biotech are likely to have a commercial background, as Wiinberg-inspired strategy of geographic expansion and a growing a pipeline of CNS products continues to bear fruit.
Denmark's CNS drugs specialist Lundbeck expects three 2013 product launches, a portfolio of new medicines and a marketing drive into markets outside anemic Europe to help offset lost revenue and profits caused by escitalopram patent expiry in the U.S. and Europe.
Lundbeck Cuts Its European Sales Teams By A Third, As It Builds Up Its Presence In the U.S. And Emerging Markets
Lundbeck becomes the latest company in Europe to announce job cuts, as austerity, generic competition and unclear pricing and reimbursement practices create uncertainties.